Related Experiment Video
Updated: Jun 14, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Molecular profiling of endometrial malignancies
Norasate Samarnthai1, Kevin Hall, I-Tien Yeh
1Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Obstetrics and Gynecology International
|April 7, 2010
Summary
Molecular profiling reveals distinct genetic changes in endometrial cancer types, aiding diagnosis and targeted therapy development. Understanding these molecular alterations is key for personalized treatment strategies.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Cancer Genetics
Background:
- Endometrial neoplasms exhibit diverse molecular profiles.
- The dualistic model categorizes endometrial carcinomas into Type I (estrogen-dependent, low-grade) and Type II (non-estrogen-dependent, high-grade).
- Understanding these molecular differences is crucial for accurate diagnosis and treatment.
Purpose of the Study:
- To elucidate the specific molecular alterations in different subtypes of endometrial neoplasms.
- To correlate molecular findings with established classifications of endometrial cancer.
- To identify potential targets for molecularly-guided therapies.
Main Methods:
- Comprehensive molecular profiling of endometrial carcinomas and sarcomas.
- Analysis of genetic mutations (e.g., PTEN, PIK3CA, KRAS, beta-catenin, p53, HER2/neu, p16), microsatellite instability, and gene fusions (JAZF1/JJAZ1).
- Assessment of loss of heterozygosity and C-MYC mutations in sarcomas.
Main Results:
- Type I endometrial carcinomas show mutations in PTEN, PIK3CA, KRAS, beta-catenin, and microsatellite instability.
- Type II endometrial carcinomas are characterized by alterations in p53, HER2/neu, p16, and E-cadherin.
- Carcinosarcomas exhibit C-MYC mutations and loss of heterozygosity; endometrial stromal sarcomas are marked by the JAZF1/JJAZ1 fusion gene.
- p53 mutations are implicated in undifferentiated endometrial sarcoma tumorigenesis.
Conclusions:
- Molecular profiling provides critical insights into the pathogenesis of endometrial neoplasms.
- Distinct molecular signatures differentiate endometrial cancer subtypes, supporting the dualistic model.
- Identified molecular changes offer a basis for improved diagnostic tools and the development of targeted therapies for endometrial cancer.
